CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Writing a Grant Part 3: The Experimental Approach

Read More
All Posts

In the previous post on grant writing, we described how to write an effective significance and innovation section, focused on defining the problem and providing a high-level overview of your proposed solution. In this post, we’ll outline the experimental approach, or research plan, wherein you’ll expand upon the solution and illustrate exactly how you plan to conduct the research.

18-BCH-27994 Blog Grant Writing Part 3 1600x800

Writing the Experimental Approach Section

As with any grant section, you’ll be much more equipped to write a comprehensible, thorough approach if you keep it structured. For example, let’s say in the significance and innovation section, you divided your research strategy into two phases; feasibility, and pre-clinical validation. A general outline for the approach section could be structured like this:

  •  Phase I – Feasibility:
    • For each Specific Aim:
      • Rationale and Hypothesis
      • Experimental Strategies
        • Milestone 1
        • Milestone 2
      • Data Collection and Statistical Analyses
      • Expected Results, Potential Pitfalls, and Alternative Approaches
      • Milestone for Phase II Transition
      • Schematic for Phase I Timeline
  • Phase II – Pre-Clinical Validation:
    • For each Specific Aim:
      • Rationale and Hypothesis
      • Experimental Strategies
        • Sub-Aim 1
        • Sub-Aim 2
      • Milestones
      • Data Collection and Statistical Analyses
      • Expected Results, Potential Pitfalls, and Alternative Approaches
      • Schematic for Phase II Timeline

Don't assume that the grant reviewers will be familiar with your proposed experimental techniques. If previously published work is critical for understanding the current studies, then include pertinent references, even if they don’t originate from your laboratory. When trying to explain complex protocols, use flow charts or diagrams instead of large bodies of text. Continue to refer to the rationale and hypothesis of each specific aim and how the proposed methodologies, analyses, and alternative tactics will address that aim. Don’t hesitate to be redundant. Take a lesson from the old saying passed down from generations of orators: “Tell them what you’re going to tell them, tell them, then tell them what you told them.”

Given the highly technical nature of the approach section and the importance of demonstrating your expertise in the field, include as much information as possible on preliminary studies. In addition, crisp, clean, polished figures are vital to storytelling and clarifying the foundation and purpose of your application. That being said, no reviewer wants to strain his or her eyes to read figure legends, so be sure to include descriptions that are simple and larger than size eight font!

Addressing Potential Pitfalls and Alternative Approaches

A vitaland often overlookedportion of the approach is the potential pitfalls and alternative approaches. Science is seldom linear, and rarely, if ever, are results perfectly aligned with your experimental plan. Knowing what could go wrong and how those unexpected mishaps will impact your timelines and budget is an integral part of your strategy.

For example, let’s say you’re pursuing a novel target for cancer and have identified a plasma biomarker that could be used to measure target engagement. One of your sub-aims is to develop an ELISA to measure this biomarker in patient samples that you plan to acquire from collaborators at another institution. Given the precious nature of the clinical samplesand your relationship with your collaboratorsyou need to ensure that you’ll get reproducible, reliable data. What happens if your ELISA doesn’t work? What if the assay-to-assay variability is too high? What if you can’t find a CRO that can validate the assay and manufacture the plates? Reviewers want to see that you’ve considered these possibilities and have identified the proper contingencies.

As has been emphasized in other posts, petition feedback from your mentors and peers regarding your approach, particularly from those who are outside your field. They will provide invaluable input on potential gaps or points of confusion in your methodology. They will also give you a gut check on whether your proposal is feasible. Can you really do this or are you trying to tackle too much?

The approach section is the bulk of your application and is the area likely to receive the most attention from reviewersonce you dazzle them with the specific aims page! Use it as an opportunity to demonstrate the value of your proposal and why your research team is the right one for the job.

Read the Complete Grant Writing Series:

Note: The National Institute of Allergy and Infectious Diseases provides sample applications along with corresponding summary statements. This is a good resource to see what gets people funded!

Tamar Aprahamian, PhD
Tamar Aprahamian, PhD
Tamar Aprahamian, PhD, is the founder of JetPub Scientific Communications, providing strategic support and high-quality writing services for the life sciences industries and academic institutions. She previously worked in academia and at a biotech start-up. In addition to serving as a reviewer for grant study sections and journals, she published 38 articles related to her research program. Tamar received her PhD in Cell, Molecular, and Developmental Biology from Tufts University - Graduate School of Biomedical Sciences.

Recent Posts

Cell Preparation Tips for Accurate Flow Cytometry Data

Generating accurate flow cytometry data requires more than just specific and sensitive antibodies validat...
Andrea Tu, PhD Nov 6, 2024

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024

Menin-KMT2A Inhibitors: A Promising Approach to Acute Myeloid Leukemia (AML) Treatment

Accounting for about 80% of adult acute leukemias, acute myeloid leukemia (AML) is an aggressive form of ...
Homa Rahnamoun, PhD Oct 16, 2024